

M. SEDKI<sup>1a,2</sup>, M. CALIZ<sup>1b</sup>, K. ALCANTARA<sup>1c</sup>, J. MCKINNEY<sup>1d</sup>, J. PRICE<sup>1d</sup>, G. WINER<sup>3</sup>, T. TOLIVER<sup>1c</sup>, M. HELLE<sup>1c</sup> and R. FOX<sup>1b</sup>

1. University of California San Francisco, CA, USA: a. Department of Epidemiology and Biostatistics, b. Division of General Internal Medicine, c. Office of Population Health, d. Division of Gastroenterology and Hepatology 2. Stanford University, Division of Gastroenterology and Hepatology. 3. Stanford, CA, USA



## INTRODUCTION

- **Women of childbearing age** with hepatitis C virus (HCV) are a key population for **prevention of vertical transmission** and improvement of maternal health outcomes.
- However, **women** are **less** likely to initiate direct acting antiviral (DAA) **treatment** compared to men, and **younger** age is associated with **lower** odds of receiving **DAA** in general.
- We identified a **cohort of women** in San Francisco with **untreated or incompletely diagnosed HCV** and implemented a targeted intervention to improve **linkage** to HCV **care**.

## AIM

To design, implement, and evaluate a prospective intervention to identify women of childbearing age with untreated or incompletely diagnosed HCV and link them to HCV care.

## METHOD

- Design: Prospective **cohort** study in San Francisco Bay Area.
- Population and Inclusion Criteria: All **women 18-50 y.o.** seen 2019-2024 at a large urban healthcare system with **EMR data**:
  - Detected** or quantifiable **HCV RNA** at most recent testing.
  - Reactive HCV antibody** without any RNA testing.
- **Manual chart review** conducted by trained navigators to extract additional lab data from outside laboratories. Patients were then **categorized** as:
  - **Requiring outreach** (RNA +, no RNA testing, no SVR labs).
  - **Not requiring outreach** (RNA undetectable).
- **Navigators called** all patients requiring outreach at least 3 times.
- **Successfully contacted** patients were offered 1) **HCV RNA testing** and other relevant bloodwork at the lab of their choice, and 2) a **telehealth linkage visit** with an **HCV provider** or with a mobile van.

## KEY TAKEAWAY

**Outreach to young women with untreated or incompletely diagnosed HCV can be achieved. EMR-based patient identification followed by telephone contact reached 44% of this population.**

## RESULTS

**Cohort:** EMR query identified **266** women age 18-50 who met EMR inclusion criteria.

- After **manual chart review**, the **cohort** consisted of **95** women with viremia or incomplete RNA testing.
- 171 had outside data showing SVR, negative RNA testing, or other reasons outreach was not needed.
- Demographics of the cohort of 95 women are shown in Table 1.

**Intervention:** **Successful telephone contact** was achieved in **44% (n=42/95)**.

- Around 60% of the cohort (n=25) agreed to a laboratory and/or linkage visit.
- Of those, **10** were confirmed currently **viremic** and **6** had **undetectable RNA**; the remaining 9 have not completed RNA testing to date.

**Outcomes:** All patients received their results and among the **10** women who were found to be **viremic**:

- **4** have been started on **DAA therapy**.
- 2 did not show for linkage visit.
- 4 were unreachable by telephone for scheduling.


Summary Linkage Results: Among the **42 women** successfully contacted by telephone:

- **10 (24%)** → **successful linkage to care**.
- 17 (40%) → declined linkage.
- 15 (36%) → unsuccessful linkage.

Table 1. Baseline characteristics and demographics of women meeting outreach eligibility criteria.

Demographics – n (%)	Total n = 95		
Age in years – mean (SD)	38.8 (6.9)	Designated PCP	7 (7%)
Race/ethnicity		Ever seen by Hepatology	16 (17%)
Non-Hispanic White	56 (59%)		
Asian	6 (6.3%)	Diabetes	2 (2%)
Latinx	7 (7.4%)	Hypertension	14 (15%)
Black/African American	7 (7.4%)	Hyperlipidemia	4 (4%)
Other	19 (20%)	Osteoporosis	0
Primary Language		Depression	11 (12%)
English	90 (95%)		
Non-English	5 (5%)	Cirrhosis	5 (5%)
Ever HCV Ab Positive	55 (58%)	Alcohol Use Disorder	6 (6%)
Ever HCV RNA Positive	61 (64%)	Steatosis	2 (2%)
Ever HCV diagnosis by ICD	50 (53%)	MASH	1 (1%)
Ever prescribed HCV medication	15 (16%)		
Currently Viremic	61 (64%)		

Figure 1. Cohort identification and linkage to HCV care results.



## CONCLUSIONS

- **EMR-based data** can identify patients with **untreated or incompletely diagnosed HCV**, though **manual chart review** remains essential for **accuracy**.
- **Dedicated navigation** led to successfully contacting **44%** of the cohort.
- Healthcare systems **can and should re-engage** and make HCV care easily available to **high-risk populations**.

## REFERENCES

Corcorran MA, Tsui JI, Scott JD, et al. Age and gender-specific hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle, Washington. Drug Alcohol Depend. 2021 Mar 1;220:108525. PMID: 33461152

## ACKNOWLEDGEMENTS

- Office of Population Health, UCSF
- Department of Epidemiology and Biostatistics, UCSF
- The San Francisco Cancer Initiative (SF CAN) led by the UCSF Helen Diller Family Comprehensive Cancer Center
- Grant # IN-US-987-7490: LISTEN – Viral Hepatitis Equity for Women, Gilead Sciences, Inc.

## CONTACT INFORMATION

- **Mai Sedki, MD MPH.**  
[mai.sedki@ucsf.edu](mailto:mai.sedki@ucsf.edu)
- **Rena Fox, MD.**  
[rena.fox@ucsf.edu](mailto:rena.fox@ucsf.edu)  
1545 Divisadero St,  
San Francisco, CA 94143



Scan me!